Diasorin SpA (CHIX:DIAM) Quality Rank

View and export this data going back to 2010. Start your Free Trial

What is Diasorin SpA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Diasorin SpA Quality Rank Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

DIA:Italy 0GZX:UK 34D:Germany DIAS:Austria

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).